We have located links that may give you full text access.
Hypopituitarism After Single-Fraction Pituitary Adenoma Radiosurgery: Dosimetric Analysis Based on Patients Treated Using Contemporary Techniques.
PURPOSE: To analyze factors associated with post-stereotactic radiosurgery (SRS) hypopituitarism among radiation-naïve patients with pituitary adenomas who underwent single-fraction SRS between 2007 and 2014.
METHODS AND MATERIALS: This was a retrospective review of 97 patients having single-fraction SRS from 2007 until 2014. Eligible patients had no history of prior radiation, normal age- and sex-specific pituitary function before SRS, and at least 24 months of endocrine follow-up. Forty patients (41%) had hormone-secreting tumors; 57 patients had nonsecreting tumors (59%). The median prescription isodose volume was 2.8 cm3 (interquartile range [IQR], 1.3-4.7); the median tumor margin dose was 20 Gy (IQR, 15-25 Gy).
RESULTS: The median follow-up after SRS was 48 months (IQR, 34-68 months). Twenty-seven patients (28%) developed pituitary insufficiency at a median of 22 months (IQR, 12-36 months) after SRS. The rate of new endocrine deficits was 17% at 2 years (95% confidence interval [CI] 10%-25%) and 31% at 5 years (95% CI 20%-42%). Male sex (hazard ratio [HR] 2.38, 95% CI 1.05-5.26, P = .04), smaller pituitary gland volume (HR 0.99, 95% CI 0.99-0.99, P = .01), and higher mean pituitary gland dose (HR 1.31, 95% CI 1.16-1.47, P < .001) were associated with post-SRS hypopituitarism in multivariable analysis. The rate of hypopituitarism for patients with a mean gland dose of <11.0 Gy at 2 years was 2% (95% CI 0%-4%) and at 5 years was 5% (95% CI 0%-11%), whereas rate of hypopituitarism for patients with a mean gland dose of ≥11.0 Gy at 2 years was 31% (95% CI 17%-43%) and at 5 years was 51% (95% CI 34%-65%).
CONCLUSIONS: Hypopituitarism after pituitary adenoma SRS increases in a time- and dose-dependent manner. Reducing the radiation exposure to the identifiable gland to a mean dose < 11.0 Gy whenever feasible may lower the incidence of new hormonal deficits after pituitary adenoma SRS.
METHODS AND MATERIALS: This was a retrospective review of 97 patients having single-fraction SRS from 2007 until 2014. Eligible patients had no history of prior radiation, normal age- and sex-specific pituitary function before SRS, and at least 24 months of endocrine follow-up. Forty patients (41%) had hormone-secreting tumors; 57 patients had nonsecreting tumors (59%). The median prescription isodose volume was 2.8 cm3 (interquartile range [IQR], 1.3-4.7); the median tumor margin dose was 20 Gy (IQR, 15-25 Gy).
RESULTS: The median follow-up after SRS was 48 months (IQR, 34-68 months). Twenty-seven patients (28%) developed pituitary insufficiency at a median of 22 months (IQR, 12-36 months) after SRS. The rate of new endocrine deficits was 17% at 2 years (95% confidence interval [CI] 10%-25%) and 31% at 5 years (95% CI 20%-42%). Male sex (hazard ratio [HR] 2.38, 95% CI 1.05-5.26, P = .04), smaller pituitary gland volume (HR 0.99, 95% CI 0.99-0.99, P = .01), and higher mean pituitary gland dose (HR 1.31, 95% CI 1.16-1.47, P < .001) were associated with post-SRS hypopituitarism in multivariable analysis. The rate of hypopituitarism for patients with a mean gland dose of <11.0 Gy at 2 years was 2% (95% CI 0%-4%) and at 5 years was 5% (95% CI 0%-11%), whereas rate of hypopituitarism for patients with a mean gland dose of ≥11.0 Gy at 2 years was 31% (95% CI 17%-43%) and at 5 years was 51% (95% CI 34%-65%).
CONCLUSIONS: Hypopituitarism after pituitary adenoma SRS increases in a time- and dose-dependent manner. Reducing the radiation exposure to the identifiable gland to a mean dose < 11.0 Gy whenever feasible may lower the incidence of new hormonal deficits after pituitary adenoma SRS.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app